BlossomHill Therapeutics Closes $71M Series A Financing

    NEXT STORY
    Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    PREV STORY
    Mr. Ron Andrews joins Precipio’s Board of Directors
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    ContraFect Appoints Michael Messinger as Chief Financial Officer

    YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...

    author_avatar
    NASDAQ Market News

    Immunocore Secures $130 Million Series B Financing

    author_avatar
    NASDAQ Market News

    Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

    First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with ...

    author_avatar
    NASDAQ Market News